{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:45:49Z","timestamp":1793148349547,"version":"4.5.0"},"reference-count":134,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:00:00Z","timestamp":1771804800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:00:00Z","timestamp":1771804800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Cardiol"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1038\/s41569-026-01265-z","type":"journal-article","created":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T17:16:42Z","timestamp":1771867002000},"page":"619-630","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Cardiotoxicity of T cell immunotherapies"],"prefix":"10.1038","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8610-3489","authenticated-orcid":false,"given":"Michael A.","family":"Raddatz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley F.","family":"Stein-Merlob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6938-1321","authenticated-orcid":false,"given":"Syed S.","family":"Mahmood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarju","family":"Ganatra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Addison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tasha L.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah M.","family":"Larson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4889-7454","authenticated-orcid":false,"given":"Eric H.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,23]]},"reference":[{"key":"1265_CR1","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1056\/NEJMra1706169","volume":"379","author":"CH June","year":"2018","unstructured":"June, C. H. & Sadelain, M. Chimeric antigen receptor therapy. N. Engl. J. Med. 379, 64\u201373 (2018). A review of chimeric antigen receptor (CAR) T cell therapy.","journal-title":"N. Engl. J. Med."},{"key":"1265_CR2","doi-asserted-by":"publisher","first-page":"4099","DOI":"10.1182\/blood-2010-04-281931","volume":"116","author":"JN Kochenderfer","year":"2010","unstructured":"Kochenderfer, J. N. et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 116, 4099\u20134102 (2010).","journal-title":"Blood"},{"key":"1265_CR3","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1056\/NEJMoa1103849","volume":"365","author":"DL Porter","year":"2011","unstructured":"Porter, D. L., Levine, B. L., Kalos, M., Bagg, A. & June, C. H. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 365, 725\u2013733 (2011).","journal-title":"N. Engl. J. Med."},{"key":"1265_CR4","doi-asserted-by":"publisher","first-page":"95ra73","DOI":"10.1126\/scitranslmed.3002842","volume":"3","author":"M Kalos","year":"2011","unstructured":"Kalos, M. et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci. Transl. Med. 3, 95ra73 (2011).","journal-title":"Sci. Transl. Med."},{"key":"1265_CR5","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.1182\/blood-2011-10-384388","volume":"119","author":"JN Kochenderfer","year":"2012","unstructured":"Kochenderfer, J. N. et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 119, 2709\u20132720 (2012).","journal-title":"Blood"},{"key":"1265_CR6","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","volume":"371","author":"SL Maude","year":"2014","unstructured":"Maude, S. L. et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371, 1507\u20131517 (2014).","journal-title":"N. Engl. J. Med."},{"key":"1265_CR7","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu, S. S. et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N. Engl. J. Med. 377, 2531\u20132544 (2017).","journal-title":"N. Engl. J. Med."},{"key":"1265_CR8","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude, S. L. et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N. Engl. J. Med. 378, 439\u2013448 (2018).","journal-title":"N. Engl. J. Med."},{"key":"1265_CR9","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","volume":"382","author":"M Wang","year":"2020","unstructured":"Wang, M. et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N. Engl. J. Med. 382, 1331\u20131342 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1265_CR10","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi, N. C. et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N. Engl. J. Med. 384, 705\u2013716 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1265_CR11","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2406526","volume":"391","author":"C Roddie","year":"2024","unstructured":"Roddie, C. et al. Obecabtagene autoleucel in adults with B-cell acute lymphoblastic leukemia. N. Engl. J. Med. 391, 2219\u20132230 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1265_CR12","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","volume":"399","author":"M Kamdar","year":"2022","unstructured":"Kamdar, M. et al. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. Lancet 399, 2294\u20132308 (2022).","journal-title":"Lancet"},{"key":"1265_CR13","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1056\/NEJMoa2116133","volume":"386","author":"FL Locke","year":"2022","unstructured":"Locke, F. L. et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N. Engl. J. Med. 386, 640\u2013654 (2022).","journal-title":"N. Engl. J. Med."},{"key":"1265_CR14","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/NEJMoa2303379","volume":"389","author":"J San-Miguel","year":"2023","unstructured":"San-Miguel, J. et al. Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. N. Engl. J. Med. 389, 335\u2013347 (2023).","journal-title":"N. Engl. J. Med."},{"key":"1265_CR15","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","volume":"388","author":"P Rodriguez-Otero","year":"2023","unstructured":"Rodriguez-Otero, P. et al. Ide-cel or standard regimens in relapsed and refractory multiple myeloma. N. Engl. J. Med. 388, 1002\u20131014 (2023).","journal-title":"N. Engl. J. Med."},{"key":"1265_CR16","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/s41591-023-02767-w","volume":"30","author":"BL Levine","year":"2024","unstructured":"Levine, B. L. et al. Unanswered questions following reports of secondary malignancies after CAR-T cell therapy. Nat. Med. 30, 338\u2013341 (2024).","journal-title":"Nat. Med."},{"key":"1265_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1113882","volume":"14","author":"A Daei Sorkhabi","year":"2023","unstructured":"Daei Sorkhabi, A. et al. The current landscape of CAR T-cell therapy for solid tumors: mechanisms, research progress, challenges, and counterstrategies. Front. Immunol. 14, 1113882 (2023).","journal-title":"Front. Immunol."},{"key":"1265_CR18","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1001\/jama.2024.19462","volume":"332","author":"JN Brudno","year":"2024","unstructured":"Brudno, J. N., Maus, M. V. & Hinrichs, C. S. CAR T cells and T-cell therapies for cancer: a translational science review. JAMA 332, 1924\u20131935 (2024).","journal-title":"JAMA"},{"key":"1265_CR19","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41416-020-01048-4","volume":"124","author":"H Raskov","year":"2021","unstructured":"Raskov, H., Orhan, A., Christensen, J. P. & G\u00f6genur, I. Cytotoxic CD8+ T cells in cancer and cancer immunotherapy. Br. J. Cancer 124, 359\u2013367 (2021).","journal-title":"Br. J. Cancer"},{"key":"1265_CR20","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s00262-004-0560-6","volume":"54","author":"L Novellino","year":"2005","unstructured":"Novellino, L., Castelli, C. & Parmiani, G. A listing of human tumor antigens recognized by T cells: March 2004 update. Cancer Immunol. Immunother. 54, 187\u2013207 (2005).","journal-title":"Cancer Immunol. Immunother."},{"key":"1265_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-020-00256-x","volume":"5","author":"J Wei","year":"2020","unstructured":"Wei, J. et al. The model of cytokine release syndrome in CAR T-cell treatment for B-cell non-Hodgkin lymphoma. Signal. Transduct. Target. Ther. 5, 134 (2020).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"1265_CR22","doi-asserted-by":"publisher","first-page":"2704","DOI":"10.1056\/NEJMra072739","volume":"358","author":"OJ Finn","year":"2008","unstructured":"Finn, O. J. Cancer immunology. N. Engl. J. Med. 358, 2704\u20132715 (2008).","journal-title":"N. Engl. J. Med."},{"key":"1265_CR23","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1038\/nm.4321","volume":"23","author":"CH June","year":"2017","unstructured":"June, C. H., Warshauer, J. T. & Bluestone, J. A. Is autoimmunity the Achilles\u2019 heel of cancer immunotherapy? Nat. Med. 23, 540\u2013547 (2017).","journal-title":"Nat. Med."},{"key":"1265_CR24","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/0952-7915(93)90054-V","volume":"5","author":"MK Jenkins","year":"1993","unstructured":"Jenkins, M. K. & Johnson, J. G. Molecules involved in T-cell costimulation. Curr. Opin. Immunol. 5, 361\u2013367 (1993).","journal-title":"Curr. Opin. Immunol."},{"key":"1265_CR25","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/0167-5699(93)90262-J","volume":"14","author":"L Chen","year":"1993","unstructured":"Chen, L., Linsley, P. S. & Hellstr\u00f6m, K. E. Costimulation of T cells for tumor immunity. Immunol. Today 14, 483\u2013486 (1993).","journal-title":"Immunol. Today"},{"key":"1265_CR26","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1126\/science.aar6711","volume":"359","author":"CH June","year":"2018","unstructured":"June, C. H., O\u2019Connor, R. S., Kawalekar, O. U., Ghassemi, S. & Milone, M. C. CAR T cell immunotherapy for human cancer. Science 359, 1361\u20131365 (2018).","journal-title":"Science"},{"key":"1265_CR27","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1158\/2159-8290.CD-12-0548","volume":"3","author":"M Sadelain","year":"2013","unstructured":"Sadelain, M., Brentjens, R. & Rivi\u00e8re, I. The basic principles of chimeric antigen receptor design. Cancer Discov. 3, 388\u2013398 (2013).","journal-title":"Cancer Discov."},{"key":"1265_CR28","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/S0140-6736(25)01030-X","volume":"406","author":"J Xu","year":"2025","unstructured":"Xu, J. et al. In-vivo B-cell maturation antigen CAR T-cell therapy for relapsed or refractory multiple myeloma. Lancet 406, 228\u2013231 (2025).","journal-title":"Lancet"},{"key":"1265_CR29","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.abm0594","volume":"375","author":"JG Rurik","year":"2022","unstructured":"Rurik, J. G. et al. CAR T cells produced in vivo to treat cardiac injury. Science 375, 91\u201396 (2022).","journal-title":"Science"},{"key":"1265_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00459-7","volume":"11","author":"RC Sterner","year":"2021","unstructured":"Sterner, R. C. & Sterner, R. M. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 11, 69 (2021).","journal-title":"Blood Cancer J."},{"key":"1265_CR31","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","volume":"17","author":"S Rafiq","year":"2020","unstructured":"Rafiq, S., Hackett, C. S. & Brentjens, R. J. Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nat. Rev. Clin. Oncol. 17, 147\u2013167 (2020).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1265_CR32","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41571-022-00704-3","volume":"20","author":"CL Flugel","year":"2023","unstructured":"Flugel, C. L. et al. Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours. Nat. Rev. Clin. Oncol. 20, 49\u201362 (2023).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1265_CR33","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/j.jcyt.2024.02.024","volume":"26","author":"MA Nix","year":"2024","unstructured":"Nix, M. A. & Wiita, A. P. Alternative target recognition elements for chimeric antigen receptor (CAR) T cells: beyond standard antibody fragments. Cytotherapy 26, 729\u2013738 (2024).","journal-title":"Cytotherapy"},{"key":"1265_CR34","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/nm.3838","volume":"21","author":"AH Long","year":"2015","unstructured":"Long, A. H. et al. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat. Med. 21, 581\u2013590 (2015).","journal-title":"Nat. Med."},{"key":"1265_CR35","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1038\/gt.2010.91","volume":"17","author":"A Hombach","year":"2010","unstructured":"Hombach, A., Hombach, A. A. & Abken, H. Adoptive immunotherapy with genetically engineered T cells: modification of the IgG1 Fc \u201cspacer\u201d domain in the extracellular moiety of chimeric antigen receptors avoids \u201coff-target\u201d activation and unintended initiation of an innate immune response. Gene Ther. 17, 1206\u20131213 (2010).","journal-title":"Gene Ther."},{"key":"1265_CR36","doi-asserted-by":"publisher","first-page":"4901","DOI":"10.4049\/jimmunol.180.7.4901","volume":"180","author":"S Wilkie","year":"2008","unstructured":"Wilkie, S. et al. Retargeting of human T cells to tumor-associated MUC1: the evolution of a chimeric antigen receptor. J. Immunol. 180, 4901\u20134909 (2008).","journal-title":"J. Immunol."},{"key":"1265_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-017-0437-8","volume":"10","author":"L Qin","year":"2017","unstructured":"Qin, L. et al. Incorporation of a hinge domain improves the expansion of chimeric antigen receptor T cells. J. Hematol. Oncol. 10, 68 (2017).","journal-title":"J. Hematol. Oncol."},{"key":"1265_CR38","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.3390\/cells9051182","volume":"9","author":"K Fujiwara","year":"2020","unstructured":"Fujiwara, K. et al. Hinge and transmembrane domains of chimeric antigen receptor regulate receptor expression and signaling threshold. Cells 9, 1182 (2020).","journal-title":"Cells"},{"key":"1265_CR39","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abc6401","volume":"13","author":"D Schneider","year":"2021","unstructured":"Schneider, D. et al. Trispecific CD19-CD20-CD22-targeting duoCAR-T cells eliminate antigen-heterogeneous B cell tumors in preclinical models. Sci. Transl. Med. 13, eabc6401 (2021).","journal-title":"Sci. Transl. Med."},{"key":"1265_CR40","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1038\/nm.4478","volume":"24","author":"Y Kagoya","year":"2018","unstructured":"Kagoya, Y. et al. A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects. Nat. Med. 24, 352\u2013359 (2018).","journal-title":"Nat. Med."},{"key":"1265_CR41","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/imr.12125","volume":"257","author":"M Chmielewski","year":"2014","unstructured":"Chmielewski, M., Hombach, A. A. & Abken, H. Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma. Immunol. Rev. 257, 83\u201390 (2014).","journal-title":"Immunol. Rev."},{"key":"1265_CR42","doi-asserted-by":"publisher","DOI":"10.4161\/2162402X.2014.994446","volume":"4","author":"M Koneru","year":"2015","unstructured":"Koneru, M., Purdon, T. J., Spriggs, D., Koneru, S. & Brentjens, R. J. IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo. Oncoimmunology 4, e994446 (2015).","journal-title":"Oncoimmunology"},{"key":"1265_CR43","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1158\/2326-6066.CIR-16-0376","volume":"5","author":"G Krenciute","year":"2017","unstructured":"Krenciute, G. et al. Transgenic expression of IL15 improves antiglioma activity of IL13R\u03b12-CAR T cells but results in antigen loss variants. Cancer Immunol. Res. 5, 571\u2013581 (2017).","journal-title":"Cancer Immunol. Res."},{"key":"1265_CR44","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01691","volume":"10","author":"Y Wang","year":"2019","unstructured":"Wang, Y. et al. An IL-4\/21 inverted cytokine receptor improving CAR-T cell potency in immunosuppressive solid-tumor microenvironment. Front. Immunol. 10, 1691 (2019).","journal-title":"Front. Immunol."},{"key":"1265_CR45","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.684642","volume":"12","author":"M Bell","year":"2021","unstructured":"Bell, M. & Gottschalk, S. Engineered cytokine signaling to improve CAR T cell effector function. Front. Immunol. 12, 684642 (2021).","journal-title":"Front. Immunol."},{"key":"1265_CR46","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1080\/15384047.2020.1739952","volume":"21","author":"S Weimin","year":"2020","unstructured":"Weimin, S., Abula, A., Qianghong, D. & Wenguang, W. Chimeric cytokine receptor enhancing PSMA-CAR-T cell-mediated prostate cancer regression. Cancer Biol. Ther. 21, 570\u2013580 (2020).","journal-title":"Cancer Biol. Ther."},{"key":"1265_CR47","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1038\/mt.2014.47","volume":"22","author":"AM Leen","year":"2014","unstructured":"Leen, A. M. et al. Reversal of tumor immune inhibition using a chimeric cytokine receptor. Mol. Ther. 22, 1211\u20131220 (2014).","journal-title":"Mol. Ther."},{"key":"1265_CR48","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.ymthe.2016.10.016","volume":"25","author":"S Mohammed","year":"2017","unstructured":"Mohammed, S. et al. Improving chimeric antigen receptor-modified T cell function by reversing the immunosuppressive tumor microenvironment of pancreatic cancer. Mol. Ther. 25, 249\u2013258 (2017).","journal-title":"Mol. Ther."},{"key":"1265_CR49","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1056\/NEJMoa1106152","volume":"365","author":"A Di Stasi","year":"2011","unstructured":"Di Stasi, A. et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N. Engl. J. Med. 365, 1673\u20131683 (2011).","journal-title":"N. Engl. J. Med."},{"key":"1265_CR50","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2014.00235","volume":"5","author":"T Gargett","year":"2014","unstructured":"Gargett, T. & Brown, M. P. The inducible caspase-9 suicide gene system as a \u201csafety switch\u201d to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells. Front. Pharmacol. 5, 235 (2014).","journal-title":"Front. Pharmacol."},{"key":"1265_CR51","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1089\/10430340460732463","volume":"15","author":"M Serafini","year":"2004","unstructured":"Serafini, M. et al. Characterization of CD20-transduced T lymphocytes as an alternative suicide gene therapy approach for the treatment of graft-versus-host disease. Hum. Gene Ther. 15, 63\u201376 (2004).","journal-title":"Hum. Gene Ther."},{"key":"1265_CR52","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1182\/blood-2014-01-545020","volume":"124","author":"B Philip","year":"2014","unstructured":"Philip, B. et al. A highly compact epitope-based marker\/suicide gene for easier and safer T-cell therapy. Blood 124, 1277\u20131287 (2014).","journal-title":"Blood"},{"key":"1265_CR53","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20221988","volume":"221","author":"M-Y Lin","year":"2024","unstructured":"Lin, M.-Y. et al. Self-regulating CAR-T cells modulate cytokine release syndrome in adoptive T-cell therapy. J. Exp. Med. 221, e20221988 (2024).","journal-title":"J. Exp. Med."},{"key":"1265_CR54","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-018-0677-2","volume":"11","author":"J Zhao","year":"2018","unstructured":"Zhao, J., Lin, Q., Song, Y. & Liu, D. Universal CARs, universal T cells, and universal CAR T cells. J. Hematol. Oncol. 11, 132 (2018).","journal-title":"J. Hematol. Oncol."},{"key":"1265_CR55","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1056\/NEJMoa2505478","volume":"394","author":"R Chiesa","year":"2026","unstructured":"Chiesa, R. et al. Universal base-edited CAR7 T cells for T-cell acute lymphoblastic leukemia. N. Engl. J. Med. 394, 152\u2013165 (2026).","journal-title":"N. Engl. J. Med."},{"key":"1265_CR56","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1056\/NEJMoa2300709","volume":"389","author":"R Chiesa","year":"2023","unstructured":"Chiesa, R. et al. Base-edited CAR7 T cells for relapsed T-cell acute lymphoblastic leukemia. N. Engl. J. Med. 389, 899\u2013910 (2023).","journal-title":"N. Engl. J. Med."},{"key":"1265_CR57","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/s41573-024-00896-6","volume":"23","author":"C Klein","year":"2024","unstructured":"Klein, C., Brinkmann, U., Reichert, J. M. & Kontermann, R. E. The present and future of bispecific antibodies for cancer therapy. Nat. Rev. Drug. Discov. 23, 301\u2013319 (2024). A review of bispecific antibody-based therapies.","journal-title":"Nat. Rev. Drug. Discov."},{"key":"1265_CR58","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/s41573-019-0028-1","volume":"18","author":"AF Labrijn","year":"2019","unstructured":"Labrijn, A. F., Janmaat, M. L., Reichert, J. M. & Parren, P. W. H. I. Bispecific antibodies: a mechanistic review of the pipeline. Nat. Rev. Drug. Discov. 18, 585\u2013608 (2019).","journal-title":"Nat. Rev. Drug. Discov."},{"key":"1265_CR59","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1038\/s41573-023-00809-z","volume":"22","author":"CA Klebanoff","year":"2023","unstructured":"Klebanoff, C. A., Chandran, S. S., Baker, B. M., Quezada, S. A. & Ribas, A. T cell receptor therapeutics: immunological targeting of the intracellular cancer proteome. Nat. Rev. Drug. Discov. 22, 996\u20131017 (2023). A review of T cell receptor therapies.","journal-title":"Nat. Rev. Drug. Discov."},{"key":"1265_CR60","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adf3700","volume":"9","author":"E Baulu","year":"2023","unstructured":"Baulu, E., Gardet, C., Chuvin, N. & Depil, S. TCR-engineered T cell therapy in solid tumors: state of the art and perspectives. Sci. Adv. 9, eadf3700 (2023).","journal-title":"Sci. Adv."},{"key":"1265_CR61","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/nature01076","volume":"419","author":"DJ Irvine","year":"2002","unstructured":"Irvine, D. J., Purbhoo, M. A., Krogsgaard, M. & Davis, M. M. Direct observation of ligand recognition by T cells. Nature 419, 845\u2013849 (2002).","journal-title":"Nature"},{"key":"1265_CR62","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/ni1058","volume":"5","author":"MA Purbhoo","year":"2004","unstructured":"Purbhoo, M. A., Irvine, D. J., Huppa, J. B. & Davis, M. M. T cell killing does not require the formation of a stable mature immunological synapse. Nat. Immunol. 5, 524\u2013530 (2004).","journal-title":"Nat. Immunol."},{"key":"1265_CR63","doi-asserted-by":"publisher","first-page":"3322","DOI":"10.1200\/JCO.2017.74.5463","volume":"35","author":"Y-C Lu","year":"2017","unstructured":"Lu, Y.-C. et al. Treatment of patients with metastatic cancer using a major histocompatibility complex class II-restricted T-cell receptor targeting the cancer germline antigen MAGE-A3. J. Clin. Oncol. 35, 3322\u20133329 (2017).","journal-title":"J. Clin. Oncol."},{"key":"1265_CR64","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1146\/annurev.immunol.26.021607.090357","volume":"26","author":"TR Malek","year":"2008","unstructured":"Malek, T. R. The biology of interleukin-2. Annu. Rev. Immunol. 26, 453\u2013479 (2008).","journal-title":"Annu. Rev. Immunol."},{"key":"1265_CR65","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/nri1901","volume":"6","author":"TA Waldmann","year":"2006","unstructured":"Waldmann, T. A. The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat. Rev. Immunol. 6, 595\u2013601 (2006).","journal-title":"Nat. Rev. Immunol."},{"key":"1265_CR66","doi-asserted-by":"publisher","first-page":"280ps7","DOI":"10.1126\/scitranslmed.aaa3643","volume":"7","author":"CH June","year":"2015","unstructured":"June, C. H., Riddell, S. R. & Schumacher, T. N. Adoptive cellular therapy: a race to the finish line. Sci. Transl. Med. 7, 280ps7 (2015). A comparative review of T cell therapies, including T cell receptor engineering, CAR T cells and tumour-infiltrating lymphocytes.","journal-title":"Sci. Transl. Med."},{"key":"1265_CR67","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1126\/science.3489291","volume":"233","author":"SA Rosenberg","year":"1986","unstructured":"Rosenberg, S. A., Spiess, P. & Lafreniere, R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233, 1318\u20131321 (1986).","journal-title":"Science"},{"key":"1265_CR68","doi-asserted-by":"publisher","first-page":"3787","DOI":"10.1200\/JCO.2015.65.5142","volume":"34","author":"AG Chapuis","year":"2016","unstructured":"Chapuis, A. G. et al. T-cell therapy using interleukin-21-primed cytotoxic T-cell lymphocytes combined with cytotoxic T-cell lymphocyte antigen-4 blockade results in long-term cell persistence and durable tumor regression. J. Clin. Oncol. 34, 3787\u20133795 (2016).","journal-title":"J. Clin. Oncol."},{"key":"1265_CR69","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.jaccao.2022.07.014","volume":"4","author":"S Ganatra","year":"2022","unstructured":"Ganatra, S., Dani, S. S., Yang, E. H., Zaha, V. G. & Nohria, A. Cardiotoxicity of T-cell antineoplastic therapies: JACC: CardioOncology primer. JACC CardioOncol. 4, 616\u2013623 (2022).","journal-title":"JACC CardioOncol."},{"key":"1265_CR70","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0343-9","volume":"6","author":"A Shimabukuro-Vornhagen","year":"2018","unstructured":"Shimabukuro-Vornhagen, A. et al. Cytokine release syndrome. J. Immunother. Cancer 6, 56 (2018).","journal-title":"J. Immunother. Cancer"},{"key":"1265_CR71","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1136\/heartjnl-2020-318083","volume":"107","author":"AF Stein-Merlob","year":"2021","unstructured":"Stein-Merlob, A. F., Rothberg, M. V., Ribas, A. & Yang, E. H. Cardiotoxicities of novel cancer immunotherapies. Heart 107, 1694\u20131703 (2021).","journal-title":"Heart"},{"key":"1265_CR72","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","volume":"24","author":"T Giavridis","year":"2018","unstructured":"Giavridis, T. et al. CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. Nat. Med. 24, 731\u2013738 (2018).","journal-title":"Nat. Med."},{"key":"1265_CR73","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","volume":"24","author":"M Norelli","year":"2018","unstructured":"Norelli, M. et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat. Med. 24, 739\u2013748 (2018).","journal-title":"Nat. Med."},{"key":"1265_CR74","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1182\/blood-2017-08-802413","volume":"130","author":"AE Obstfeld","year":"2017","unstructured":"Obstfeld, A. E. et al. Cytokine release syndrome associated with chimeric-antigen receptor T-cell therapy: clinicopathological insights. Blood 130, 2569\u20132572 (2017).","journal-title":"Blood"},{"key":"1265_CR75","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/s41568-020-00323-z","volume":"21","author":"RC Larson","year":"2021","unstructured":"Larson, R. C. & Maus, M. V. Recent advances and discoveries in the mechanisms and functions of CAR T cells. Nat. Rev. Cancer 21, 145\u2013161 (2021).","journal-title":"Nat. Rev. Cancer"},{"key":"1265_CR76","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","volume":"385","author":"DW Lee","year":"2015","unstructured":"Lee, D. W. et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 385, 517\u2013528 (2015).","journal-title":"Lancet"},{"key":"1265_CR77","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1158\/2159-8290.CD-16-0040","volume":"6","author":"DT Teachey","year":"2016","unstructured":"Teachey, D. T. et al. Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Cancer Discov. 6, 664\u2013679 (2016).","journal-title":"Cancer Discov."},{"key":"1265_CR78","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee, D. W. et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol. Blood Marrow Transpl. 25, 625\u2013638 (2019).","journal-title":"Biol. Blood Marrow Transpl."},{"key":"1265_CR79","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15215149","volume":"15","author":"T Fugere","year":"2023","unstructured":"Fugere, T. et al. Immune effector cell-associated HLH-like syndrome: a review of the literature of an increasingly recognized entity. Cancers 15, 5149 (2023).","journal-title":"Cancers"},{"key":"1265_CR80","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/j.jaci.2020.09.016","volume":"146","author":"SW Canna","year":"2020","unstructured":"Canna, S. W. & Cron, R. Q. Highways to hell: mechanism-based management of cytokine storm syndromes. J. Allergy Clin. Immunol. 146, 949\u2013959 (2020).","journal-title":"J. Allergy Clin. Immunol."},{"key":"1265_CR81","doi-asserted-by":"publisher","first-page":"438.e1","DOI":"10.1016\/j.jtct.2023.03.006","volume":"29","author":"MR Hines","year":"2023","unstructured":"Hines, M. R. et al. Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome. Transplant. Cell. Ther. 29, 438.e1\u2013438.e16 (2023).","journal-title":"Transplant. Cell. Ther."},{"key":"1265_CR82","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.hoc.2025.02.005","volume":"39","author":"JC Lee","year":"2025","unstructured":"Lee, J. C., Johnson, W. T., Hines, M. & Shah, N. N. Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS). Hematol. Oncol. Clin. North. Am. 39, 617\u2013643 (2025).","journal-title":"Hematol. Oncol. Clin. North. Am."},{"key":"1265_CR83","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","volume":"368","author":"SA Grupp","year":"2013","unstructured":"Grupp, S. A. et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N. Engl. J. Med. 368, 1509\u20131518 (2013).","journal-title":"N. Engl. J. Med."},{"key":"1265_CR84","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1161\/CIRCRESAHA.121.319077","volume":"128","author":"PM Ridker","year":"2021","unstructured":"Ridker, P. M. & Rane, M. Interleukin-6 signaling and anti-interleukin-6 therapeutics in cardiovascular disease. Circ. Res. 128, 1728\u20131746 (2021).","journal-title":"Circ. Res."},{"key":"1265_CR85","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.cyto.2014.12.024","volume":"74","author":"JA Fontes","year":"2015","unstructured":"Fontes, J. A., Rose, N. R. & \u010cih\u00e1kov\u00e1, D. The varying faces of IL-6: from cardiac protection to cardiac failure. Cytokine 74, 62\u201368 (2015).","journal-title":"Cytokine"},{"key":"1265_CR86","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a016295","volume":"6","author":"T Tanaka","year":"2014","unstructured":"Tanaka, T., Narazaki, M. & Kishimoto, T. IL-6 in inflammation, immunity, and disease. Cold Spring Harb. Perspect. Biol. 6, a016295 (2014).","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"1265_CR87","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.4049\/jimmunol.1601778","volume":"198","author":"P Ranganathan","year":"2017","unstructured":"Ranganathan, P. et al. Serum miR-29a is upregulated in acute graft-versus-host disease and activates dendritic cells through TLR binding. J. Immunol. 198, 2500\u20132512 (2017).","journal-title":"J. Immunol."},{"key":"1265_CR88","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1093\/eurheartj\/ehad117","volume":"44","author":"SS Mahmood","year":"2023","unstructured":"Mahmood, S. S. et al. Biomarkers and cardiovascular outcomes in chimeric antigen receptor T-cell therapy recipients. Eur. Heart J. 44, 2029\u20132042 (2023). An analysis of biomarker prediction of cardiovascular outcomes after CAR T cell therapy.","journal-title":"Eur. Heart J."},{"key":"1265_CR89","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1200\/JCO.1995.13.3.688","volume":"13","author":"G Fyfe","year":"1995","unstructured":"Fyfe, G. et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J. Clin. Oncol. 13, 688\u2013696 (1995).","journal-title":"J. Clin. Oncol."},{"key":"1265_CR90","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1182\/blood-2013-03-490565","volume":"122","author":"GP Linette","year":"2013","unstructured":"Linette, G. P. et al. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood 122, 863\u2013871 (2013).","journal-title":"Blood"},{"key":"1265_CR91","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-017-3854-8","volume":"17","author":"V Jaravine","year":"2017","unstructured":"Jaravine, V., M\u00f6sch, A., Raffegerst, S., Schendel, D. J. & Frishman, D. Expitope 2.0: a tool to assess immunotherapeutic antigens for their potential cross-reactivity against naturally expressed proteins in human tissues. BMC Cancer 17, 892 (2017).","journal-title":"BMC Cancer"},{"key":"1265_CR92","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.799206","volume":"12","author":"Y Zhang","year":"2021","unstructured":"Zhang, Y. et al. Single-cell analysis of target antigens of CAR-T reveals a potential landscape of \u201con-target, off-tumor toxicity\u201d. Front. Immunol. 12, 799206 (2021).","journal-title":"Front. Immunol."},{"key":"1265_CR93","doi-asserted-by":"publisher","first-page":"S306","DOI":"10.1016\/j.htct.2024.05.005","volume":"46","author":"A Rodrigues Dos Santos","year":"2024","unstructured":"Rodrigues Dos Santos, A., Zanini, D. & Andolfatto, D. Cytokine release syndrome after chimeric antigen receptor T cell therapy in patients with diffuse large B-cell lymphoma: a systematic review. Hematol. Transfus. Cell Ther. 46, S306\u2013S315 (2024).","journal-title":"Hematol. Transfus. Cell Ther."},{"key":"1265_CR94","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1016\/j.jacc.2021.08.044","volume":"78","author":"A Goldman","year":"2021","unstructured":"Goldman, A. et al. Adverse cardiovascular and pulmonary events associated with chimeric antigen receptor T-cell therapy. J. Am. Coll. Cardiol. 78, 1800\u20131813 (2021). A database analysis of the incidence of cardiopulmonary adverse events after CAR T cell therapy.","journal-title":"J. Am. Coll. Cardiol."},{"key":"1265_CR95","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.924208","volume":"12","author":"L-R Chen","year":"2022","unstructured":"Chen, L.-R. et al. Cardiovascular effects associated with chimeric antigen receptor T cell therapy in cancer patients: a meta-analysis. Front. Oncol. 12, 924208 (2022).","journal-title":"Front. Oncol."},{"key":"1265_CR96","doi-asserted-by":"publisher","first-page":"3099","DOI":"10.1016\/j.jacc.2019.10.038","volume":"74","author":"RM Alvi","year":"2019","unstructured":"Alvi, R. M. et al. Cardiovascular events among adults treated with chimeric antigen receptor T-cells (CAR-T). J. Am. Coll. Cardiol. 74, 3099\u20133108 (2019). A registry analysis of cardiotoxicity of CAR T cell therapy, including an analysis of the impact of tocilizumab.","journal-title":"J. Am. Coll. Cardiol."},{"key":"1265_CR97","volume":"7","author":"D Koeckerling","year":"2024","unstructured":"Koeckerling, D. et al. Cardiovascular events after chimeric antigen receptor T-cell therapy for advanced hematologic malignant neoplasms: a meta-analysis. JAMA Netw. Open 7, e2437222 (2024).","journal-title":"Open"},{"key":"1265_CR98","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102504","volume":"69","author":"F Korell","year":"2024","unstructured":"Korell, F. et al. Evaluation of all-cause mortality and cardiovascular safety in patients receiving chimeric antigen receptor T cell therapy: a prospective cohort study. EClinicalMedicine 69, 102504 (2024).","journal-title":"EClinicalMedicine"},{"key":"1265_CR99","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.jaccao.2020.04.012","volume":"2","author":"B Lefebvre","year":"2020","unstructured":"Lefebvre, B. et al. Cardiovascular effects of CAR T cell therapy: a retrospective study. JACC CardioOncol. 2, 193\u2013203 (2020).","journal-title":"JACC CardioOncol."},{"key":"1265_CR100","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1111\/bjh.19497","volume":"205","author":"R Shouval","year":"2024","unstructured":"Shouval, R. et al. Atrial arrhythmias following CAR-chimeric antigen receptor T-cell therapy: Incidence, risk factors and biomarker profile. Br. J. Haematol. 205, 978\u2013989 (2024).","journal-title":"Br. J. Haematol."},{"key":"1265_CR101","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s11936-024-01041-7","volume":"26","author":"SZ Qamer","year":"2024","unstructured":"Qamer, S. Z. et al. Cardiotoxicities of chimeric antigen receptor T-cell therapy and bispecific T-cell antibodies. Curr. Treat. Options Cardiovasc. Med. 26, 175\u2013187 (2024).","journal-title":"Curr. Treat. Options Cardiovasc. Med."},{"key":"1265_CR102","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/j.jaccao.2023.07.009","volume":"5","author":"B Lefebvre","year":"2023","unstructured":"Lefebvre, B. et al. Incidence of MACE in patients treated with CAR-T cell therapy: a prospective study. JACC CardioOncol. 5, 747\u2013754 (2023).","journal-title":"JACC CardioOncol."},{"key":"1265_CR103","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1161\/CIRCULATIONAHA.120.048100","volume":"142","author":"S Ganatra","year":"2020","unstructured":"Ganatra, S. et al. Chimeric antigen receptor T-cell therapy-associated cardiomyopathy in patients with refractory or relapsed non-Hodgkin lymphoma. Circulation 142, 1687\u20131690 (2020).","journal-title":"Circulation"},{"key":"1265_CR104","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-06035-4","volume":"23","author":"Y Liu","year":"2025","unstructured":"Liu, Y. et al. Risk analysis of cardiovascular toxicity in patients with lymphoma treated with CD19 CAR T cells. J. Transl. Med. 23, 8 (2025).","journal-title":"J. Transl. Med."},{"key":"1265_CR105","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1038\/s41409-020-0956-8","volume":"55","author":"S Fiorenza","year":"2020","unstructured":"Fiorenza, S., Ritchie, D. S., Ramsey, S. D., Turtle, C. J. & Roth, J. A. Value and affordability of CAR T-cell therapy in the United States. Bone Marrow Transpl. 55, 1706\u20131715 (2020).","journal-title":"Bone Marrow Transpl."},{"key":"1265_CR106","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.e19500","volume":"39","author":"B Sahli","year":"2021","unstructured":"Sahli, B., Eckwright, D., Darling, E., Gleason, P. P. & Leach, J. W. Chimeric antigen receptor T-cell therapy real-world assessment of total cost of care and clinical events for the treatment of relapsed or refractory lymphoma [abstract]. J. Clin. Oncol. 39, e19500 (2021).","journal-title":"J. Clin. Oncol."},{"key":"1265_CR107","doi-asserted-by":"publisher","first-page":"404.e1","DOI":"10.1016\/j.jtct.2022.03.021","volume":"28","author":"SJ Keating","year":"2022","unstructured":"Keating, S. J., Gu, T., Jun, M. P. & McBride, A. Health care resource utilization and total costs of care among patients with diffuse large B cell lymphoma treated with chimeric antigen receptor T cell therapy in the United States. Transplant. Cell. Ther. 28, 404.e1\u2013404.e6 (2022).","journal-title":"Transplant. Cell. Ther."},{"key":"1265_CR108","doi-asserted-by":"publisher","DOI":"10.1161\/circ.150.suppl_1.4138101","volume":"150","author":"J Song","year":"2024","unstructured":"Song, J. et al. CAR-T-associated cardiovascular events are associated with increased resource utilization [abstract]. Circulation 150, 4138101 (2024).","journal-title":"Circulation"},{"key":"1265_CR109","doi-asserted-by":"publisher","first-page":"6282","DOI":"10.1182\/bloodadvances.2024013849","volume":"8","author":"M Munir","year":"2024","unstructured":"Munir, M., Sayed, A., Addison, D. & Epperla, N. Cardiovascular toxicities associated with novel cellular immune therapies. Blood Adv. 8, 6282\u20136296 (2024).","journal-title":"Blood Adv."},{"key":"1265_CR110","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008518","volume":"12","author":"A Sayed","year":"2024","unstructured":"Sayed, A. et al. Cardiovascular toxicities associated with bispecific T-cell engager therapy. J. Immunother. Cancer 12, e008518 (2024). A database analysis of adverse events after bispecific antibody therapy.","journal-title":"J. Immunother. Cancer"},{"key":"1265_CR111","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/s43856-024-00540-9","volume":"4","author":"B Karthikeyan","year":"2024","unstructured":"Karthikeyan, B. et al. Cardiotoxic profiles of CAR-T therapy and bispecific T-cell engagers in hematological cancers. Commun. Med. 4, 116 (2024).","journal-title":"Commun. Med."},{"key":"1265_CR112","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101133","volume":"4","author":"Q Pan","year":"2023","unstructured":"Pan, Q. et al. Phase 1 clinical trial to assess safety and efficacy of NY-ESO-1-specific TCR T cells in HLA-A\u221702:01 patients with advanced soft tissue sarcoma. Cell Rep. Med. 4, 101133 (2023).","journal-title":"Cell Rep. Med."},{"key":"1265_CR113","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008668","volume":"12","author":"M Wermke","year":"2024","unstructured":"Wermke, M. et al. First-in-human dose escalation trial to evaluate the clinical safety and efficacy of an anti-MAGEA1 autologous TCR-transgenic T cell therapy in relapsed and refractory solid tumors. J. Immunother. Cancer 12, e008668 (2024).","journal-title":"J. Immunother. Cancer"},{"key":"1265_CR114","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0522-3","volume":"7","author":"EI Buchbinder","year":"2019","unstructured":"Buchbinder, E. I. et al. Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition. J. Immunother. Cancer 7, 49 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"1265_CR115","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1056\/NEJMoa2210233","volume":"387","author":"MW Rohaan","year":"2022","unstructured":"Rohaan, M. W. et al. Tumor-infiltrating lymphocyte therapy or ipilimumab in advanced melanoma. N. Engl. J. Med. 387, 2113\u20132125 (2022).","journal-title":"N. Engl. J. Med."},{"key":"1265_CR116","doi-asserted-by":"publisher","first-page":"2656","DOI":"10.1200\/JCO.21.00612","volume":"39","author":"AA Sarnaik","year":"2021","unstructured":"Sarnaik, A. A. et al. Lifileucel, a tumor-infiltrating lymphocyte therapy, in metastatic melanoma. J. Clin. Oncol. 39, 2656\u20132666 (2021).","journal-title":"J. Clin. Oncol."},{"key":"1265_CR117","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1097\/CJI.0000000000000341","volume":"44","author":"MG Fradley","year":"2021","unstructured":"Fradley, M. G. et al. Cardiovascular toxicity and mortality associated with adoptive cell therapy and tumor-infiltrating lymphocytes for advanced stage melanoma. J. Immunother. 44, 86\u201389 (2021).","journal-title":"J. Immunother."},{"key":"1265_CR118","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-024-03420-0","volume":"22","author":"J Guo","year":"2024","unstructured":"Guo, J. et al. IL-2-free tumor-infiltrating lymphocyte therapy with PD-1 blockade demonstrates potent efficacy in advanced gynecologic cancer. BMC Med. 22, 207 (2024).","journal-title":"BMC Med."},{"key":"1265_CR119","doi-asserted-by":"publisher","first-page":"3153","DOI":"10.1016\/j.jacc.2019.10.049","volume":"74","author":"S Ganatra","year":"2019","unstructured":"Ganatra, S. et al. Chimeric antigen receptor T-cell therapy for cancer and heart: JACC Council perspectives. J. Am. Coll. Cardiol. 74, 3153\u20133163 (2019). An expert opinion on pretherapy evaluation and optimization before CAR T cell therapy and monitoring and management during therapy.","journal-title":"J. Am. Coll. Cardiol."},{"key":"1265_CR120","first-page":"2452","volume":"141","author":"C Gutierrez","year":"2023","unstructured":"Gutierrez, C., Neilan, T. G. & Grover, N. S. How I approach optimization of patients at risk of cardiac and pulmonary complications after CAR T-cell therapy. Blood 141, 2452\u20132459 (2023).","journal-title":"Blood"},{"key":"1265_CR121","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.jaccao.2020.06.005","volume":"2","author":"AJ Kanelidis","year":"2020","unstructured":"Kanelidis, A. J. et al. CardioMEMS-guided CAR T cell therapy for lymphoma in a patient with anthracycline-induced cardiomyopathy. JACC CardioOncol. 2, 515\u2013518 (2020).","journal-title":"JACC CardioOncol."},{"key":"1265_CR122","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1080\/17434440.2024.2347412","volume":"21","author":"A Maraey","year":"2024","unstructured":"Maraey, A., Chacko, P. & Moukarbel, G. V. Thoracic impedance monitoring in heart failure: from theory to practice. Expert. Rev. Med. Devices 21, 459\u2013462 (2024).","journal-title":"Expert. Rev. Med. Devices"},{"key":"1265_CR123","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1016\/j.bbmt.2020.08.036","volume":"26","author":"A Guha","year":"2020","unstructured":"Guha, A. et al. Cardiovascular events associated with chimeric antigen receptor T cell therapy: cross-sectional FDA adverse events reporting system analysis. Biol. Blood Marrow Transpl. 26, 2211\u20132216 (2020).","journal-title":"Biol. Blood Marrow Transpl."},{"key":"1265_CR124","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1182\/bloodadvances.2024013688","volume":"9","author":"A Bajwa","year":"2025","unstructured":"Bajwa, A. et al. Siltuximab for chimeric antigen receptor T-cell therapy-related CRS and ICANS: a multicenter retrospective analysis. Blood Adv. 9, 170\u2013175 (2025).","journal-title":"Blood Adv."},{"key":"1265_CR125","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1038\/s41591-023-02404-6","volume":"29","author":"JH Park","year":"2023","unstructured":"Park, J. H. et al. CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results. Nat. Med. 29, 1710\u20131717 (2023).","journal-title":"Nat. Med."},{"key":"1265_CR126","doi-asserted-by":"publisher","first-page":"3978","DOI":"10.1200\/JCO.21.01992","volume":"39","author":"BD Santomasso","year":"2021","unstructured":"Santomasso, B. D. et al. Management of immune-related adverse events in patients treated with chimeric antigen receptor T-cell therapy: ASCO guideline. J. Clin. Oncol. 39, 3978\u20133992 (2021).","journal-title":"J. Clin. Oncol."},{"key":"1265_CR127","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1634\/theoncologist.2018-0028","volume":"23","author":"RQ Le","year":"2018","unstructured":"Le, R. Q. et al. FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome. Oncologist 23, 943\u2013947 (2018).","journal-title":"Oncologist"},{"key":"1265_CR128","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1080\/1744666X.2019.1629904","volume":"15","author":"C Kotch","year":"2019","unstructured":"Kotch, C., Barrett, D. & Teachey, D. T. Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome. Expert. Rev. Clin. Immunol. 15, 813\u2013822 (2019). A review of the use of tocilizumab in the setting of CAR T cell therapy cytokine release syndrome.","journal-title":"Expert. Rev. Clin. Immunol."},{"key":"1265_CR129","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.124.039977","volume":"14","author":"C Quartermaine","year":"2025","unstructured":"Quartermaine, C. et al. Presence of clonal hematopoiesis and cardiac events after allogeneic stem cell transplantation. J. Am. Heart Assoc. 14, e039977 (2025).","journal-title":"J. Am. Heart Assoc."},{"key":"1265_CR130","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S0140-6736(03)15326-3","volume":"363","author":"N Pathan","year":"2004","unstructured":"Pathan, N. et al. Role of interleukin 6 in myocardial dysfunction of meningococcal septic shock. Lancet 363, 203\u2013209 (2004).","journal-title":"Lancet"},{"key":"1265_CR131","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1016\/j.hrthm.2023.08.026","volume":"20","author":"X Li","year":"2023","unstructured":"Li, X. et al. Selective blockade of interleukin 6 trans-signaling depresses atrial fibrillation. Heart Rhythm 20, 1759\u20131770 (2023).","journal-title":"Heart Rhythm"},{"key":"1265_CR132","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.758157","volume":"12","author":"J Liao","year":"2021","unstructured":"Liao, J. et al. Interleukin-6-mediated-Ca2+ handling abnormalities contributes to atrial fibrillation in sterile pericarditis rats. Front. Immunol. 12, 758157 (2021).","journal-title":"Front. Immunol."},{"key":"1265_CR133","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41409-024-02429-6","volume":"60","author":"A Rampotas","year":"2025","unstructured":"Rampotas, A., Richter, J., Isenberg, D. & Roddie, C. CAR-T cell therapy embarks on autoimmune disease. Bone Marrow Transpl. 60, 6\u20139 (2025).","journal-title":"Bone Marrow Transpl."},{"key":"1265_CR134","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1161\/CIRCULATIONAHA.115.010484","volume":"132","author":"AM Bellinger","year":"2015","unstructured":"Bellinger, A. M. et al. Cardio-oncology: how new targeted cancer therapies and precision medicine can inform cardiovascular discovery. Circulation 132, 2248\u20132258 (2015).","journal-title":"Circulation"}],"container-title":["Nature Reviews Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41569-026-01265-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41569-026-01265-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41569-026-01265-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T12:01:25Z","timestamp":1786622485000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41569-026-01265-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,23]]},"references-count":134,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1265"],"URL":"https:\/\/doi.org\/10.1038\/s41569-026-01265-z","relation":{},"ISSN":["1759-5002","1759-5010"],"issn-type":[{"value":"1759-5002","type":"print"},{"value":"1759-5010","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,23]]},"assertion":[{"value":"8 February 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"E.H.Y. reports research grants from Amgen, Bristol Myers Squibb, Janssen Research and Development, and Novo Nordisk; consulting fees from Edwards Lifesciences and Xencor; and honoraria from Zoll Medical. The other authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}